Published in Neurology on February 08, 2011
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (2011) 1.90
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol (2003) 1.70
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med (2009) 1.63
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics (2012) 1.52
Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy. J Virol (2007) 1.52
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS (2005) 1.39
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol (2007) 1.36
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. PLoS One (2013) 1.27
Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol (2011) 1.26
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother (2010) 1.19
Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler (2003) 1.16
Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr (2011) 1.16
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis (2011) 1.13
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies. Curr Neurol Neurosci Rep (2008) 1.04
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS (2006) 1.03
HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity. Nat Clin Pract Neurol (2007) 1.03
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics (2006) 1.03
Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care (2011) 1.01
11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol (2012) 1.00
African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis (2010) 0.99
A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One (2007) 0.97
Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav (2011) 0.96
The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol (2013) 0.96
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr (2012) 0.95
Neurologic manifestations of human immunodeficiency virus-2: dementia, myelopathy, and neuropathy in West Africa. J Neurovirol (2011) 0.95
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS (2009) 0.95
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials (2007) 0.94
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr (2013) 0.93
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol (2007) 0.91
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol (2013) 0.91
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology (2012) 0.91
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother (2012) 0.90
Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials (2007) 0.89
Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics (2012) 0.89
Atypical PML leading to a diagnosis of common variable immunodeficiency. Neurology (2005) 0.87
HIV peripheral neuropathy progression: protection with glucose-lowering drugs? J Neurovirol (2012) 0.86
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol (2012) 0.85
Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol (2012) 0.85
Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy. Mult Scler (2010) 0.85
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother (2012) 0.84
Simplification of the research diagnosis of HIV-associated sensory neuropathy. HIV Clin Trials (2009) 0.84
Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere. Neurology (2012) 0.83
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr (2006) 0.82
Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol (2013) 0.81
Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology (2012) 0.81
Family history of dementia predicts worse neuropsychological functioning among HIV-infected persons. J Neuropsychiatry Clin Neurosci (2011) 0.81
Therapeutic conundrum: AIDS therapies may be double-edged swords. Neurology (2010) 0.81
The manifold faces of PML and the challenge of diagnosis. Neurology (2011) 0.79
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol (2014) 0.79
Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol (2014) 0.77
Histoplasmoma: isolated central nervous system infection with Histoplasma capsulatum in a patient with AIDS. Case report and brief review of the literature. Clin Neurol Neurosurg (2006) 0.77
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. HIV Clin Trials (2010) 0.76
Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res (2016) 0.76
Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology (2010) 0.76
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr (2016) 0.75
Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med (2013) 0.75
Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen. J Neurovirol (2015) 0.75
Time is brain for infections too? Neurology (2011) 0.75
Viral escape in cerebrospinal fluid--an achilles heel of HIV therapy? J Infect Dis (2010) 0.75
Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain (2015) 0.75
Susac syndrome in a patient with human immunodeficiency virus infection. J Neurovirol (2013) 0.75
Tumefactive demyelination in a patient with human immunodeficiency virus. J Neurovirol (2013) 0.75
Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. J Acquir Immune Defic Syndr (2014) 0.75
Part 2: history of 20th century neurology: decade by decade. Ann Neurol (2003) 0.75